Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases

Abstract Introduction Without the clear immunophenotyping of brain metastases (BrMs), the optimal treatment strategy based on PD-1/PD-L1 inhibitor for patients with non-small-cell lung cancer (NSCLC) and BrMs remains unknown. Methods 308 patients with NSCLC received PD-1/PD-L1 inhibitor-based monoth...

Full description

Bibliographic Details
Main Authors: Haowei Wang, Fangfang Liu, Xiaoxia Chen, Chao Zhao, Xuefei Li, Caicun Zhou, Jie Hu, Qian Chu, Tao Jiang
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Experimental Hematology & Oncology
Subjects:
Lung cancer
PD-1
Brain metastases
Tumor immune microenvironment
Online Access:https://doi.org/10.1186/s40164-023-00412-3

Internet

https://doi.org/10.1186/s40164-023-00412-3

Similar Items